ACIU vs. CUE, IMMP, SELB, KNTE, AKBA, FULC, MACK, ADCT, ZVRA, and CTXR
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Cue Biopharma (CUE), Immutep (IMMP), Selecta Biosciences (SELB), Kinnate Biopharma (KNTE), Akebia Therapeutics (AKBA), Fulcrum Therapeutics (FULC), Merrimack Pharmaceuticals (MACK), ADC Therapeutics (ADCT), Zevra Therapeutics (ZVRA), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical preparations" industry.
AC Immune vs.
AC Immune (NASDAQ:ACIU) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
AC Immune has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500.
AC Immune currently has a consensus target price of $13.00, suggesting a potential upside of 475.22%. Cue Biopharma has a consensus target price of $8.33, suggesting a potential upside of 123.41%. Given AC Immune's higher possible upside, equities research analysts plainly believe AC Immune is more favorable than Cue Biopharma.
In the previous week, Cue Biopharma had 3 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for Cue Biopharma and 0 mentions for AC Immune. AC Immune's average media sentiment score of 1.32 beat Cue Biopharma's score of 0.45 indicating that AC Immune is being referred to more favorably in the media.
Cue Biopharma has lower revenue, but higher earnings than AC Immune. Cue Biopharma is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.
16.8% of AC Immune shares are held by institutional investors. Comparatively, 31.9% of Cue Biopharma shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 10.2% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
AC Immune has a net margin of 0.00% compared to Cue Biopharma's net margin of -12,005.79%. AC Immune's return on equity of -38.85% beat Cue Biopharma's return on equity.
AC Immune received 112 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 62.50% of users gave AC Immune an outperform vote while only 50.92% of users gave Cue Biopharma an outperform vote.
Summary
AC Immune beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
